Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The product will be launched by NATCO's commercial partner Viatris.
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The campaign aims to promote an integrated view by combining Ayurveda and Yoga to create harmony not just within the body, but also in our minds
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The integration and transition of the brands are expected to be completed by June 2022.
Subscribe To Our Newsletter & Stay Updated
